Lipocine Inc., a biopharmaceutical company, has announced a license, development and supply agreement with SPC Korea granting exclusive rights to market TLANDO, its oral testosterone replacement therapy, in South Korea.
 
Under the terms of the distribution and license agreement, Lipocine will receive an upfront payment and is also eligible to receive certain regulatory and sales milestone payments, including payment upon regulatory approval of TLANDO in South Korea. Lipocine is entitled to royalties on net commercial sales. Lipocine will supply TLANDO to SPC Korea and will receive a supply price. SPC Korea will assume responsibility for obtaining regulatory approval within the territory.
 
“We are very pleased to partner TLANDO with SPC Korea,” said Dr. Mahesh Patel, President and Chief Executive Officer of Lipocine. “This license agreement represents a strategic opportunity to expand the global reach of TLANDO and to address the significant unmet medical need in South Korea. It underscores Lipocine’s commitment to strategic partnerships that have the potential to drive growth and create value for our shareholders while advancing our goals to deliver innovative therapies to patients.”
 
Earlier this month, Lipocine announced an exclusive supply and distribution agreement with Pharmalink to commercialize TLANDO in the Gulf Cooperation Council (GCC) countries.